Evidence map›Paper›PMID 41675228›Full record

ArticleMaterials today. Bio2026

Engineered BioAIE photosensitizer from natural cryptolepine: Amplifying type I/II ROS for photodynamic eradication of bacteria.

Hongtao Kong, Yuanbo Li, Saiya Yang, Zhi-Hao Li, Ruirui Li, Yuequan Wu, Lina Ding, Daran Li, Shuhui Qi, Ya-Na Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongtao KongSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Yuanbo LiSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Saiya YangSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Zhi-Hao LiState Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China.
Ruirui LiSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Yuequan WuSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Lina DingSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Daran LiSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Shuhui QiSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
Ya-Na WangSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.
En ZhangSchool of Pharmaceutical Sciences, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Zhengzhou University, Zhengzhou, 450001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The escalating threat of antimicrobial resistance (AMR) necessitates urgent development of novel antibacterial agents. Photodynamic therapy (PDT) emerges as a promising alternative strategy due to its non-invasiveness and low resistance development risk. And natural products provide ideal scaffolds for photosensitizer (PS) design owing to inherent bioactivity and biocompatibility. Herein, we reported a structurally modified natural products derived aggregation-induced emission photosensitizer (BioAIE-PS), TPA-CRY, engineered from the natural alkaloid cryptolepine (CRY) for combating bacterial infections and biofilms. This molecular redesign successfully overcame the detrimental aggregation-caused quenching (ACQ) effect and weak reactive oxygen species (ROS) generation intrinsic to native CRY. Notably, upon photoexcitation, TPA-CRY demonstrated substantially enhanced ROS production and superior

Indexed as

Aggregation-induced emissionAntibacterial activityBiofilmCryptolepinePhotodynamic therapyReactive oxygen species

Identifiers

PMID41675228
PMCPMC12888752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.